PHASE 2, SINGLE ARM STUDY OF CG0070 COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER (NMIBC) UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN (BCG)

被引：0
|
作者：
Li, Roger [1 ]
Steinberg, Gary [2 ]
Uchio, Edward [3 ]
Lamm, Donald [4 ]
Paras, Shah [5 ]
Kamat, Ashish [6 ]
Bivalacqua, Trinity [7 ]
Packiam, Vignesh [8 ]
Chisamore, Michael [9 ]
McAdory, John [10 ]
Grandi, Paola [10 ]
Hnat, Nataliya [10 ]
Burke, James [10 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res, Tampa, FL USA
[2] NYU Langone Hlth, New York, NY USA
[3] Univ Calif Irvine, Irvine, CA USA
[4] BCG Oncol, Phoenix, AZ USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Texas MD Anderson, Houston, TX USA
[7] Univ Penn, Philadelphia, PA 19104 USA
[8] Univ Iowa, Iowa City, IA USA
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] CG Oncol, Irvine, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0666
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
666
引用
收藏
页码：A696 / A696
页数：1
相关论文
共 50 条
  • [31] Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.
    Kamat, Ashish M.
    Shore, Neal D.
    Hahn, Noah M.
    Alanee, Shaheen Riadh
    Nishiyama, Hiroyuki
    Shariat, Shahrokh F.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Steinberg, Gary D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Phase II clinical trial of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib for the treatment of high-risk nonmuscle-invasive bladder cancer (NMIBC).
    Helfand, Alexander M.
    Lee, Cheryl T.
    Hafez, Khaled
    Hussain, Maha
    Liebert, Monica
    Daignault, Stephanie
    Montgomery, Jeffrey Scott
    Miller, David Christopher
    Drnek, Linda
    Hollenbeck, Brent K.
    Weizer, Alon Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [33] A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
    Li, Roger
    Sexton, Wade J.
    Dhillon, Jasreman
    Berglund, Anders
    Naidu, Shreyas
    Borjas, Gustavo
    Rose, Kyle
    Kim, Youngchul
    Wang, Xuefeng
    Conejo-Garcia, Jose R.
    Jain, Rohit K.
    Poch, Michael A.
    Spiess, Philippe E.
    Pow-Sang, Julio
    Gilbert, Scott M.
    Zhang, Jingsong
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3875 - 3881
  • [34] Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
    Owen Alan Edwards Cooper
    Ola Ghatnekar
    Natalia Piglowska
    Charlie A. Smith
    Paul Swinburn
    James W. F. Catto
    Günter Niegisch
    Jørn Skibsted Jakobsen
    PharmacoEconomics - Open, 2023, 7 : 469 - 477
  • [35] Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
    Cooper, Owen Alan Edwards
    Ghatnekar, Ola
    Piglowska, Natalia
    Smith, Charlie A.
    Swinburn, Paul
    Catto, James W. F.
    Niegisch, Guenter
    Jakobsen, Jorn Skibsted
    PHARMACOECONOMICS-OPEN, 2023, 7 (03) : 469 - 477
  • [36] Utilization of Bacillus Calmette- Guerin for Nonmuscle Invasive Bladder Cancer in an Era of Bacillus Calmette-Guerin Supply Shortages REPLY
    Khanna, Abhinav
    Abouassaly, Robert
    UROLOGY, 2019, 124 : 126 - 126
  • [37] PHASE 2 KEYNOTE-057 STUDY: PEMBROLIZUMAB FOR PATIENTS WITH HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER UNRESPONSIVE TO BACILLUS CALMETTE-GUERIN
    Kulkarini, Girish S.
    de Wit, Ronald
    Balar, Arjun V.
    Kamat, Ashish
    Uchio, Edward
    Mourey, Loic
    Krieger, Laurence
    Singer, Eric A.
    Bajorin, Dean
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuku
    Konety, Badarinath
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara
    Boormans, Joost L.
    JOURNAL OF UROLOGY, 2019, 201 (04): : E616 - E616
  • [38] HEALTHCARE RESOURCE USE (HCRU) OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PATIENTS POST BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE STATUS IN MULTIPLE COUNTRIES
    Broughton, E.
    Chun, D.
    Gooden, K.
    Mycock, K.
    Rajkovic, I
    Taylor-Stokes, G.
    VALUE IN HEALTH, 2020, 23 : S484 - S485
  • [39] COFORMULATED VIBOSTOLIMAB/PEMBROLIZUMAB OR COFORMULATED FAVEZELIMAB/PEMBROLIZUMAB FOR BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): COHORT C OF PHASE 2 KEYNOTE-057 TRIAL
    Shilpa, Gupta
    Neal, Shore
    Girish, Kulkarni
    Andrea, Necchi
    Hema, Dave
    Ekta, Kapadia
    Qing, Zhao
    Ashish, Kamat
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [40] Updated Interim Analysis from Keynote-057: Pembrolizumab Monotherapy for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
    Krieger, Laurence
    de Wit, Ronald
    Kulkarni, Girish S.
    Uchio, Edward M.
    Boormans, Joost L.
    Roumiguie, Mathieu
    Singer, Eric A.
    Bajorin, Dean F.
    Kamat, Ashish M.
    Grivas, Petros
    Seo, Ho Kyung
    Nishiyama, Hiroyuki
    Konety, Badrinath R.
    Nam, Kijoeng
    Kapadia, Ekta
    Frenkl, Tara L.
    Balar, Arjun Vasant
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 52 - 53
12345